Atlas Trials

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

Clinical trial NCT05069610 · COMPLETED

Trial details

NCT number
NCT05069610
Sponsor
Advagene Biopharma Co. Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2022-03-21
Primary completion
2023-10-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.